By the mid-1990s, about 15 million American women were taking HRT, making it the nation's most prescribed drug class. Pharmaceutical companies matched demand with robust supply, doctors prescribed confidently, and women took it without today's anxieties. Reliable clinical, commercial, and cultural infrastructure supported the treatment.
Then came 1998, and the launch of the Women's Health Initiative study, the largest randomized trial of HRT ever conducted. The results, published in 2002, would dismantle that infrastructure almost overnight.
The WHI's findings, announced in July 2002, were alarming on their face: HRT, specifically the combination of conjugated equine estrogen and synthetic progestin used in the trial, was linked to increased risks of breast cancer, blood clots, stroke, and heart disease. Study administrators halted the trial early.
The news traveled fast.
"Women were scared and confused. Like every other clinician in this country, I was inundated with calls and visits from patients."
— Dr. JoAnn Manson, Chief of Preventive Medicine,
Brigham and Women's Hospital; WHI Investigator
Almost overnight, roughly 80 percent of American women using HRT quit. Sales of Prempro plummeted. Physicians grew cautious, and for more than twenty years, fewer than 5% of menopausal women used hormone therapy. The 1990s consensus had shifted to institutional fear.
The problem, the devastating, inexcusable problem, is that the study was significantly flawed in ways that took years to fully understand, and that those flaws were never communicated to the public with anything like the urgency of the original findings.
The WHI studied women with an average age of 63, a full decade or more past the onset of menopause, already at elevated cardiovascular risk simply due to age. It used a single oral formulation at relatively high doses, rather than the lower-dose transdermal patches many women were already using. Its findings were applied universally to all women, of all ages, using all formulations, a sweeping generalization the data could not support.
- 63 average age of WHI study participants — a decade past typical menopause onset
- 80% The number of women using HRT stopped cold turkey after the 2002 announcement.
- 91,000 estimated women who died prematurely of CVD after stopping HRT, per Yale research
The reanalysis came slowly. Researchers found that the elevated cancer risk in the combined HRT group amounted to roughly four additional cases per 1,000 women over five years, a risk smaller than that associated with drinking alcohol regularly or being obese, and one that did not translate into increased breast cancer mortality. For women who began HRT within ten years of menopause or before the age of 60, cardiovascular outcomes were actually favorable. The drug that had been declared dangerous was, for most of the women who needed it, beneficial.
But by then, the damage was done. The medical community had moved on. Manufacturers scaled back production, and the infrastructure collapsed. One Yale study estimated more than 91,000 women between 50 and 59 died prematurely from cardiovascular disease after the WHI publication. The resulting panic had devastating consequences.
INTERLUDE ⛓️💥 · 1998
The Year Viagra Launched and Everything Was Fine
It is worth stepping back to 1998, the same year the WHI study began enrolling participants, because something else happened in medicine that year that makes for an uncomfortable comparison.
Sildenafil, or Viagra, was approved in March 1998 for erectile dysfunction. Within two weeks, American doctors wrote 40,000 prescriptions per week. It quickly became one of the fastest-selling drugs. There were no prolonged safety warnings, no mass-media panic, or years of clinical hesitation. Demand was met swiftly and at scale.
Testosterone replacement therapy follows a similar pattern. Men facing symptoms of low testosterone can access a wide range of gels, patches, injections, and pellets. Telehealth makes TRT simple to obtain. Supply chains are stable, and national shortages have never occurred. There’s no uncertainty around men’s right to feel well.
WOMEN — ESTROGEN / HRT
The institutional response to demand
- Peak: 15 million users in the mid-1990s
- 2002: 80% stopped overnight after one study
- 20+ years of sub-5% prescribing rates
- Supply chain allowed to atrophy.
- The 2025 shortage is projected to last up to 3 years.
- Women pharmacy-hopping, rationing doses.
MEN — VIAGRA / TESTOSTERONE (TRT)
The institutional response to demand
- Viagra: 40,000 scripts/week within 2 weeks of launch
- No sustained safety panic or mass discontinuation
- The TRT market is robust and growing.
- Telehealth access is widely and easily available.
- No national supply shortage reported
- Treated as a straightforward medical priority
The key difference is not the medications themselves, but the foundational cultural assumption each received. When men's well-being was disrupted, the medical system responded quickly to restore it. When women's well-being was threatened, the system categorized relief as risky, debated its validity for years, and let the infrastructure collapse.
ACT THREE 🎬· 2023–PRESENT
The Comeback — and the Shelves Are Empty
The rehabilitation of HRT has been gradual, then sudden. Social media accelerated a conversation that had been building in peer-reviewed journals for years. Women began sharing experiences, comparing notes, pushing back on the advice they'd been given for decades. Physicians started revisiting the literature. The FDA's position shifted quietly, then dramatically, culminating in July 2025 when Commissioner Marty Makary publicly called HRT "lifesaving," and in November 2025 when the agency removed its longstanding safety warning entirely.
The demand response was immediate. Prescriptions for estrogen patches jumped 26 percent in the months following the November announcement. Overall patch use has risen 184 percent since 2023. Telehealth platforms report patch sales up 150 percent. By early 2026, roughly 5 in 100 women aged 45–54 had been prescribed estrogen-based HRT, roughly double the rate of just three years prior. The pent-up demand of twenty lost years is arriving all at once.
"When the FDA removed the safety warning in November, it created unprecedented demand that cannot fully be met at present."
— Sandoz spokesperson; Swiss generics manufacturer
And the supply chain, the one that was never rebuilt after 2002, cannot keep up. Major manufacturers, including Amneal, Zydus, Sandoz, Noven, and Viatris, all have doses in shortage. Industry insiders say the crisis could last up to three years. New production lines and manufacturing facilities take years to build, and estrogen patches are generic medicines with slim profit margins, offering manufacturers little financial incentive to invest rapidly. Women are pharmacy-hopping, rationing doses, switching brands mid-treatment, or going without.
THE RECKONING
What the Shortage Is Really Made Of
The 2025–2026 estrogen patch shortage is a policy failure. But it is also something older and less flattering: the downstream consequence of a medical culture that has consistently treated women's health as secondary, as more complicated, more risky, less urgent than men's.
The NIH did not require that federally funded research include female subjects until 1993. Drug approval trials have historically skewed male. The single most consequential study ever conducted on a treatment used by 15 million women was misread, miscommunicated, and allowed to reshape clinical practice for an entire generation without adequate correction. Meanwhile, a drug for male sexual function launched in the same decade to international celebration and has never faced a supply problem in its history.
"People have waited a long time to make a decision about whether they want to use hormones," said Dr. Mary Rosser of Columbia University. "Then they make the decision — and then they can't get them."
No one has ever said that about Viagra!
